Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium infantis BX-01
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium infantis BX-01 is a probiotic bacterial strain belonging to the species Bifidobacterium longum subsp. infantis, commonly found in the intestines of breastfed infants. This strain is used as a live biotherapeutic product and dietary supplement to support gut health, modulate immune function, and promote healthy development of the gastrointestinal microbiome in infants. Mechanistically, B. infantis strains are known for their ability to metabolize human milk oligosaccharides (HMOs), produce short-chain fatty acids (notably acetate), exert anti-inflammatory effects by suppressing pro-inflammatory cytokines, and inhibit pathogenic microbes through production of biosurfactants and bacteriocins[1][3][4]. Clinical studies with related strains have shown benefits in reducing symptoms of irritable bowel syndrome (IBS), lowering risk of necrotizing enterocolitis (NEC) in preterm infants, improving weight gain in undernourished infants, and supporting overall immune development[1][4][6]. The specific BX-01 strain is marketed primarily for pediatric use but may also be included in multi-strain probiotic formulations.
- Other names
- 婴儿双歧杆菌BX-01Bifidobacterium longum subsp. infantis BX-01
Beyond the preview
Go deeper on Bifidobacterium infantis BX-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium infantis BX-01.